The SARS-CoV-2 pandemic brought new challenges and opportunities to biotech and pharmaceutical companies. Several new vaccines and therapies have already been brought to patients. Companies initiated efforts to catalyze collaborative research, new ways of working and social justice. One year into the pandemic, we will examine the initial lessons for biopharma R&D - what worked, what didn’t, and how can the industry sustain momentum on emerging priorities for the future? Join us for a discussion with three of the industry’s top leaders.